Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab + Chemotherapy in Refractory/Relapsed AML
NCT00006045Phase 3Unknown
- Sponsor
- Facet Biotech Corporation
- Start
- Mar 2000
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of lintuzumab in acute myeloid leukemia (AML), sponsored by Facet Biotech Corporation. Status: unknown.
02
Drugs
lintuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00006045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006045.